Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether esomeprazole changes withdrawals due to adverse events at 8 weeks compared with fluticasone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events at 12 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Biologics showed no clear difference in withdrawals due to adverse events 12 to 44 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination diet with omeprazole changes withdrawals due to adverse events at 8 to 12 weeks compared with omeprazole (very low certainty).
1 finding from 1 review
Any adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Serious adverse events with use of FMT for induction of remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Any adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC
Fecal microbiota transplantation showed no clear difference in any adverse events with use of FMT for induction of remission in UC… compared with control (low certainty).
1 finding from 1 review
Serious adverse events with use of FMT for induction of remission in UC (RR > 1 favors control) · people with active UC
It is very uncertain whether fecal microbiota transplantation changes serious adverse events with use of FMT for induction of remission in… compared with control (very low certainty).
1 finding from 1 review